The long-term objective of this proposal is to gain insight into mechanisms of cell-mediated immunity and unresponsiveness to intracellular pathogens in humans. Leprosy provides an extraordinary model to investigate these immunoregulatory processes. First, the disease primarily affects skin and is therefore accessible for study, proving a unique opportunity for investigating the immune response at the site of infection. Secondly, the disease represents a spectrum, in which the clinical manifestations correlate with the immune response to the pathogen. In particular, patients with the resistant tuberculoid form (T-Lep) express type 1 cytokines in lesions;whereas patients with progressive lepromatous form (L-Lep) manifest type 2 cytokines in lesions. Our progress {3942} and preliminary data indicate that i) disease lesion transcriptome analysis provides a new level of insight into immunologic mechanisms that contribute to host defense in humans;ii) TCR V?6 T cell clones derived from T-lep patients are activated by a bacterial lipoglycoprotein (LprG);and iii) foam cells in L-lep lesions are M? that contain host-derived oxidized phospholipids, a major component of mildly oxidized low density lipoprotein (LDL). We hypothesize that the outcome of the host response to M. leprae is determined by the nature of the innate and adaptive immune response in lesions. We now propose to: 1) elucidate the site of disease-host gene expression profiles associated with resistance versus susceptibility in the human immune response to an intracellular pathogen, 2) elucidate the mechanism by which T-cell recognition of a major microbial antigen, LprG contributes to host defense at the site of disease in leprosy;and, 3) investigate the mechanism by which host-derived lipids accumulate in macrophages in leprosy lesions. The studies we propose are intended to provide a comprehensive analysis of the immune response in leprosy, comparing host responses in patients that are resistant to infection vs. susceptible to progressive disease. We anticipate that such studies will provide new insights into mechanisms of immunoregulation in humans, and, we would hope, would provide the ability to predict disease outcome and also lead to the development of new immunomodulatory treatments for a variety of human infectious diseases.

Public Health Relevance

To Public Health We have chosen to study leprosy, because it remains a global health burden on developing countries, because it provides an extraordinary model to study human immune responses to a microbial pathogen and because it is skin disease, such that the lesions are readily accessible for study of immune processes at the site of disease. Our preliminary data demonstrate unique insights into human immune responses from the study of leprosy, including the biologic/immunologic pathways that contribute to resistance vs. susceptibility to progressive infection, a novel type of bacterial protein, containing both lipid and carbohydrate modifications, that is recognized by T cells, and the role of host lipid metabolism in regulating host immune responses against microbial pathogens. The investigation of these aspects of host defense mechanisms will yield new insights into the human immune system as well as provide novel targets for therapeutic intervention against a wide range of infectious diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI022553-28
Application #
8197716
Study Section
Clinical Research and Field Studies of Infectious Diseases Study Section (CRFS)
Program Officer
Parker, Tina M
Project Start
1991-01-01
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
28
Fiscal Year
2012
Total Cost
$588,244
Indirect Cost
$173,040
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Schenk, Mirjam; Fabri, Mario; Krutzik, Stephan R et al. (2014) Interleukin-1* triggers the differentiation of macrophages with enhanced capacity to present mycobacterial antigen to T cells. Immunology 141:174-80
Montoya, Dennis; Inkeles, Megan S; Liu, Phillip T et al. (2014) IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci Transl Med 6:250ra114
Teles, Rosane M B; Graeber, Thomas G; Krutzik, Stephan R et al. (2013) Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 339:1448-53
Liu, Philip T; Wheelwright, Matthew; Teles, Rosane et al. (2012) MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med 18:267-73
Schenk, Mirjam; Krutzik, Stephan R; Sieling, Peter A et al. (2012) NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy. Nat Med 18:555-63
Modlin, Robert L (2012) Innate immunity: ignored for decades, but not forgotten. J Invest Dermatol 132:882-6
Fabri, Mario; Realegeno, Susan E; Jo, Eun-Kyeong et al. (2011) Role of autophagy in the host response to microbial infection and potential for therapy. Curr Opin Immunol 23:65-70
Fabri, Mario; Stenger, Steffen; Shin, Dong-Min et al. (2011) Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 3:104ra102
Cruz, Daniel; Wang, Zhiming; Kibbie, Jon et al. (2011) Diversity through phosphine catalysis identifies octahydro-1,6-naphthyridin-4-ones as activators of endothelium-driven immunity. Proc Natl Acad Sci U S A 108:6769-74
Lee, Delphine J; Li, Huiying; Ochoa, Maria T et al. (2010) Integrated pathways for neutrophil recruitment and inflammation in leprosy. J Infect Dis 201:558-69

Showing the most recent 10 out of 21 publications